Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

NCT07331272 is registered in ClinicalTrials.gov with Nanjing Legend Biotech Co. as lead sponsor.

NCT NCT07331272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07331272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
Lead sponsor
Nanjing Legend Biotech Co.
Phase
Phase 1
Overall status
Recruiting
Start date
January 29, 2026
Completion date
January 31, 2030
Enrollment
38 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathies(iim), systemic lupus erythematosus (sle)